BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 1310104)

  • 1. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
    Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
    J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
    Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
    J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
    Miller AA; Tolley EA; Niell HB; Griffin JP; Mauer AM
    J Clin Oncol; 1993 Jun; 11(6):1179-88. PubMed ID: 8388920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
    Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
    Minami H; Ando Y; Sakai S; Shimokata K
    J Clin Oncol; 1995 Jan; 13(1):191-9. PubMed ID: 7799020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
    Miller AA; Tolley EA; Niell HB
    Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.
    Felip E; Massuti B; Camps C; Benito D; Isla D; González-Larriba JL; López-Cabrerizo MP; Salamanca O; Puerto-Pica J; Moyano A; Baselga J; Rosell R
    Clin Cancer Res; 1998 Nov; 4(11):2723-8. PubMed ID: 9829735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.
    Thompson DS; Hainsworth JD; Hande KR; Holzmer MC; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1322-8. PubMed ID: 8315429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Ozols RF
    J Clin Oncol; 1995 Aug; 13(8):1860-70. PubMed ID: 7543559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.
    Saxman S; Loehrer PJ; Logie K; Stephens D; Workman F; Scullin D; Einhorn LH; Ansari R
    Invest New Drugs; 1991 Aug; 9(3):253-6. PubMed ID: 1664423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma.
    Hainsworth JD; Stroup SL; Greco FA
    Cancer; 1996 Jun; 77(12):2458-63. PubMed ID: 8640693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prolonged oral etoposide therapy in advanced stage lung cancer].
    Bozóky G; Ruby E; Góhér I; Mohos A; Lengyel M
    Orv Hetil; 1997 Jul; 138(28):1791-5. PubMed ID: 9280873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
    Grunberg SM; Crowley J; Livingston R; Gill I; Williamson SK; O'Rourke T; Braun T; Marshall ME; Weick JK; Balcerzak SP
    J Clin Oncol; 1993 Aug; 11(8):1598-601. PubMed ID: 8393099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.
    Mehdi SA; Perry MC; Herndon JE; Crawford J; Young R; Graziano SL
    J Interferon Cytokine Res; 1998 Aug; 18(8):623-7. PubMed ID: 9726444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.
    Lee JS; Scott C; Komaki R; Fossella FV; Dundas GS; McDonald S; Byhardt RW; Curran WJ
    J Clin Oncol; 1996 Apr; 14(4):1055-64. PubMed ID: 8648357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
    Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
    Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.